Nebicapone
- Generic Name
- Nebicapone
- Drug Type
- Small Molecule
- Chemical Formula
- C14H11NO5
- CAS Number
- 274925-86-9
- Unique Ingredient Identifier
- NM2KXJ990T
- Background
Nebicapone is under investigation in clinical trial NCT03097211 (Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg).
Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With "Wearingoff" Phenomenon
Phase 2
Completed
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2017-04-06
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 254
- Registration Number
- NCT03103399
Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg
Phase 1
Completed
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 38
- Registration Number
- NCT03097211
- Locations
- 🇵🇹
Human Pharmacology Unit (UFH) - BIAL - Portela & Cª, SA, S. Mamede do Coronado, Portugal
Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 22
- Registration Number
- NCT02772627
- Locations
- 🇵🇹
Human Pharmacology Unit - BIAL - Portela & Ca, S.A., S. Mamede do Coronado, Portugal
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath